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Antimicrobial peptides (AMPs) are compounds serving as natural antibiotics. 
LL-37, the member of cathelicidin antimicrobial peptides, is known to be mainly 
produced by epithelial cells and crucial role in innate immune response from the 
first line of host defense after bacterial infection. LL-37 increases or decreases pro-
inflammatory cytokines including IFN-β, IL-6 or IL-1β. However, the role of LL-
37 in the immune system is not yet clearly understood. Recent studies have 
proposed that LL-37 is excessively produced in chronic skin diseases such as 
rosacea and psoriasis. But, the pathogenesis of rosacea has not been studied in 
detail yet. In this study, I examined the role of LL-37 in the innate immune 
responses. Here, I demonstrated that LL-37 induces NLRP3 inflammasome 
activation. I also had found that the mechanism of LL-37-mediated NLRP3 
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inflammasome activation in bone marrow-derived macrophages (BMDMs). In 
addition, inhibition of potassium efflux and reduction of intracellular calcium 
levels failed to trigger the activation of caspase-1 and IL-1β secretion from 
BMDMs. I had also shown that internalized LL-37 caused lysosomal leakage and 
cathepsin B-mediated NLRP3 inflammasome activation in BMDMs. Subsequently, 
I examined the potential effect of the NLRP3 inflammasome complex in rosacea 
mice model, which induced by LL-37 injection. Interestingly, I observed that the 
lesion and the release of IL-1β were markedly reduced in Nlrp3-deficient mice, but 
not in wild type mice. Taken together, I suggest that LL-37-induced NLRP3 
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Innate immune system constitutes the first line of host defense to avoid pathogens. It 
is mainly happened by macrophages and dendritic cells (DCs) as well as non-professional 
cells such as epithelial cells and endothelial cells.1 These cells have Pattern recognition 
receptors (PRRs), which recognize the pathogen-associated molecular patterns (PAMPs) or 
damage-associated molecular patterns (DAMP). There are four types of PRR families, 
including the Toll-like receptors (TLRs), C-type lectin receptors (CLRs), Retinoic acid-
inducible gene (RIG)-I-like receptors (RLRs) and nucleotide-binding oligomerization 
domain (NOD)-like receptors (NLRs).2,3 In response to infection and tissue injuries, PRRs 
up-regulate the transcription of genes associated with inflammatory response. PRRs-
mediated inflammation mediators include cytokines such as type I interferons (IFNs), pro-
interleukin 1-beta (pro-IL-1β), tumor necrosis factor (TNF) and interleukin-6 (IL-6).4,5 
Whereas TNF and IL-6 are released as it produced, the expulsion of IL-1β requires another 
PRRs activation steps, called as “inflammasome”.6,7  
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Inflammasome is a cytosolic multi-protein complex. In response to various stimuli, it 
is assembled, promotes the cleavage of caspase-1, subsequently processes IL-1β and IL-18, 
responsible for the initiation of inflammation.8,9 Five sensor proteins have been identified 
as inflammasome components, including NLR family pyrin domain-containing 1, 3 
(NLRP1, NLRP3), NLR family CARD domain-containing protein 4 (NLRC4), the proteins 
absent in melanoma 2 (AIM2) and pyrin.10 Among them, NLRP3 inflammasome responds 
to diverse stimuli, including crystalline, particulate matter (such as MSU, silica, asbestos 
and alum), extracellular ATP and nigericin.11-13 Although the underlying mechanism of 
NLRP3 activation is still poorly understood, two-step activation mechanism by priming 
signal (signal 1) and activation signal (signal 2) is generally accepted. Priming signal 
provided by inflammatory stimuli such as TLR4 agonists induces the IL-1β and NLRP3 
expression and then Second signal triggered by DAMPs and PAMPs, promotes NLRP3 
inflammasome assembly and caspase-1 mediated-IL-1β and IL-18 and pyroptosis.14,15 
Antimicrobial peptides (AMPs) are the part of innate immune response to protect the 
host against invading microbes.16 The cathelicidin family of AMPs play an essential role in 
the immune defense especially in mammals. It is abundantly produced in damaged tissues. 
They participate in the immune system by directly killing microbes or increasing host 
defense mechanisms.17-19 Although several cathelicidin peptides exist, LL-37 is the only 
member of the human cathelicidin family. LL-37 is produced by cleavage of hCAP18 that 
is a cationic antimicrobial 18-kDa polypeptide.20,21  
Previous reports showed that LL-37 mediates Type І interferon production by forming 
self-RNA or DNA complexes.22-25 Production of type I IFNs is generally promoted by the 
recognition of TLR3, TLR7 and TLR9 in endosomes as well as DAI and RIG-I in 
cytosol.26 This mechanism is caused by DNA and RNA of the invading microbe, but not by 
self-DNA and RNA.24 However, the self-DNA and RNA from the damaged cells are 
complexed with LL-37 to be recognized by TLR3, TLR7, TLR9 or RIG-I for the 
production of type I IFNs. In additions, LL-37 can induce process and release of IL-1β in 
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monocytes and bone marrow-derived macrophages (BMDMs). However, the specific 
mechanisms how LL-37 induces IL-1β release remain unclear.  
On the other hand, LL-37 has also an anti-inflammatory effects.27 LL-37 can form a 
complex with lipopolysaccharide (LPS) to prevent LPS from interacting with TLR4.20,28,29 
The LL-37/LPS complex reduces IL-6 production as a result of TLR4 signaling. Moreover, 
LL-37 can interact with DNA to form LL-37/DNA complex which do not trigger the 
activation of caspase-1.30 Therefore, Effects of LL-37 on the inflammation still remains 
controversial. 
Rosacea, atopic dermatitis and psoriasis are characterized by chronic inflammatory 
skin diseases.31-33 Although the exact pathogenesis of these diseases is not completely 
understood, innate immune response plays an important role in these disease. Since some 
studies shown abnormal expression or function of LL-37 inflamed lesion of skin disease, 
LL-37 have been proposed as an important molecule in the progression of inflammatory 
skin diseases including rosacea. Rosacea is characterized by erythema, pustules and 
telangiectasia and affects an estimated 14 million Americans (1 in 20 people).34 Although 
the cause of rosacea is unknown, It is mainly characterized by an excessive increase in 
active LL-37 as well as abnormalities in vascularity.21,32,35 However, the undoubting 
mechanisms of LL-37 on the pathogenesis of rosacea still remains unclear. 
LL-37 is one of the molecule to protect host against external microbes. The original 
role is beneficial to the host, but LL-37 can cause inflammation in certain environments. A 
recent study has revealed that LL-37 is associated with PRRs signaling. As mentioned 
above, LL-37 mediates both pro-inflammatory and anti-inflammatory effects.27 In this 
report, I tried to identify the relation between LL-37 and PRRs signaling. Of particular 
interest, LL-37/LPS complex decreases IL-6 production. However, surprisingly, LL-37 and 
LPS increase IL-1β production. Here, I examined that LL-37 is related to inflammasome 
and also provided that LL-37 plays a potential role in rosacea disease. 
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Ⅱ. MATERIAL & METHODS 
 
1. Mice 
C57BL/6, Nlrp3-/- were from the Jackson Laboratory. All mice strains were 
administered in Yonsei University College of medicine. Entire mice were maintained under 
specific pathogen-free conditions. All experiments were in compliance with the Guide for 
Care and Use of Laboratory Animals and approved by the Institutional Ethical Committee, 
Yonsei University College of Medicine.  
 
2. Reagents and antibodies 
LL-37 was obtained from Invivogen (San Diego, CA, USA). Lipopolysaccharide 
(LPS), ATP, nigericin, glibenclamide, BAPTA-AM and poly (dA;dT) were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). CA-074 was purchased from ENZO Life Sciences 
(Farmingdale, NY, USA). Acridine orange was obtained from Thermo Fisher scientific 
(Waltham, MA, USA). 
Mouse monoclonal anti-caspase-1 (p20) antibody and mouse monoclonal anti-
NLRP3/NALP3 antibody were purchased from Adipogen (San Diego, CA, USA). Goat 
polyclonal anti-IL-1β/IL-1F2 antibody was purchased from R&D systems (Minneapolis, 
MN, USA). Rabbit monoclonal anti-ASC antibody was purchased from Cell Signaling 
Technology (Danvers, MA, USA). Mouse monoclonal anti-β-actin antibody and rabbit 
monoclonal anti-caspase-1 (p10) antibody was purchased from Santa Cruz (Santa Cruz, 
CA, USA). 
 
3. Cell cultures  
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Primary BMDMs were isolated from femurs and tibias of C57BL/6 mice or Nlrp3 -/- 
mice. Harvested bone marrow progenitor cells were maintained in 8% L929 conditional 
Dulbecco’s modified Eagle’s medium (DMEM) (Corning, NY, USA) media, supplemented 
with 10% fetal bovine serum (FBS) (Corning), 100 U/mL penicillin and streptomycin 
(Gibco, Gran Island, NY, USA). After 4 days, culture medium was replaced with 5% L929-
conditional fresh complete DMEM and then adherent cells were plated in appropriated 
plates. All cells were incubated in a 37 ̊C incubator filled with 5% CO2. 
 
4. Mice treatment and measurement of skin thickness 
The back of adult mice (6-10 weeks) were shaved using a razor 24 hrs before 
treatment and removed completely with hair removal cream. The thickness of the back 
tissue was measured before LL-37 injection. LL-37 were intradermally injected on the 
back with 40 μl of peptide (50, 300 μM) twice a day. 48 hrs after the initial injection, skin 
was measured thickness and then biopsied for western blotting and hematoxylin-eosin 
(H&E) staining.  
 
5. Immunoblot analysis 
Cells were lysed by cross-linking buffer containing 20 mM HEPES (pH 7.5), 0.5 % 
NP-40, 50 mM KCl, 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, phosphatase inhibitors 
and protease inhibitors. Cell culture supernatants were precipitated by methanol-
chloroform extraction method. Soluble cell lysates and culture supernatants were 
fractionated by SDS-PAGE gels and then transferred onto PVDF membranes (Bio-Rad, 
Hercules, CA, USA). 
6. Quantification of mRNA  
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To measure mRNA production, total RNA was extracted using TRIzol reagent 
(Invitrogen) and reverse transcribed using PrimeScriptTMRT Master Mix (Takara clontech, 
Mountain view, CA, USA) according to the manufacturer’s method. Quantitative real-time 
PCR was performed using SYBR Premix Ex Taq (Takara) and detected by a StepOnePlus 
real-time PCR system (Applied Biosystems, Foster city, CA, USA). 
 
7. Measurement of cytokine production 
Secreted cytokines were measured in cell-free supernatants using ELISA. Mouse IL-
1β and IL-6 enzyme-linked immunoassay (ELISA) kits were obtained from R&D 
(Minneapolis, MN, USA).  
 
8. Immunofluorescence assay   
Cells grown on coverslip in a 12-well plate or 24-well plate were fixed with 4% 
formaldehyde and permeabilized with 0.2% Triton X-100. After blocking with 4% BSA, 
cells were incubated with primary antibodies targeting LL-37 (Santa Cruz), phalloidin 
(Thermo Fisher), LAMP-1 (Santa Cruz) followed by the Cy3- or Alexa Fluor 488-
conjugated anti-mouse or anti-rabbit IgG (Jackson Immuno Research or Invitrogen). Cells 
were then observed by confocal microscopy (Zeiss, LSM700). 
 
9. Measurement of ions by ICP-OES 
To measure ions inside cells, treated cells were washed by triple distilled water 
(T.D.W) and dissolved with 5% Nitric acid. Dissolved cells were analyzed by using 
Inductively Coupled Plasma Optical Emission Spectrometer (ICP-OES) (OPTIMA 8300, 
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perkin elmer, MA, USA). 
 
10. Measurement of lysosomal rupture by flow cytometry 
For flow cytometry-based monitoring of lysosomal rupture, treated cells were washed 
in fluorescence-activated cell sorting (FACS) buffer (PBS with 10 % FBS) and stained 
with 0.3 µg/ml acridine orange reagent (Thermo Fisher scientific, Waltham, MA, USA) for 
10 mins, 37°C. Next, stained cells were collected by centrifugation (500 g, 3 mins) and 
resuspended with FACS buffer for analysis using flow cytometry (FACS Verse, Beckman 
coulter, CA, USA). 
 
11. Statistical analysis 
All values were expressed as the mean ± standard error of the mean (SEM) of 
individual samples. Groups were compared using t-test or one-way ANOVA with a 
bonferroni post-test. P-value of < 0.05 demonstrates statistically significant. Analyses were 
performed using GraphPad Prism program.  
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Table 1. Primer sequence for PCR 
Primer sequence 
Target Sequence 
Mouse IL-6 Forward: 5’- AGTTGCCTTCTTGGGACTGA -3’ 
Reverse: 5’- TCCACGATTTCCCAGGAGAC -3’ 
Mouse IL-1β Forward: 5’- GCCCATCCTCTGTGACTCAT -3’ 
Reverse: 5’- AGGCCACAGGTATTTTGTCG -3’ 
Mouse IFN-β Forward: 5’-TTCCTGCTGTGCTTCTTCAC -3’ 
Reverse: 5’- CTTTCCATTCAGCTGCTCCA -3’ 
Mouse Rn18s Forward: 5’- CGCGGTTCTATTTTGTTGGT -3’ 
Reverse: 5’- AGTCGGCATCGTTTATGGTC -3’ 
Mouse VEGF-A Forward: 5’- CA GGCTGCTGTAACGATGAA -3’ 
Reverse: 5’- TTTCTTGCGCTTTCGTTTT -3’ 
  




1. LL-37 enhances dsRNA-triggered IFN-β production in macrophages 
TLR3, one of the pattern recognition receptors (PRRs) is located in the endolysosome, 
recognizes dsRNA to produce type Ⅰ IFNs through TRIF, TBK1 signaling.36 Previous 
studies suggested that LL-37 promotes IFN-β production by dsRNA in keratinocytes or 
plasmacytoid dendritic cell (pDC).23,25 However, the production of interleukin-6 (IL-6) and 
interleukin-8 (IL-8) upon TLR3 is reduced by LL-37.25 To investigate the production of 
IFN-β and other pro-inflammatory cytokines in BMDMs, cells other than keratinocytes or 
pDC, BMDMs were pre-treated with LL-37 for 1 hr, and then poly(I:C), similar to dsRNA 
treatment. The IFN-β mRNA was induced by poly(I:C) treatment, but higher amounts were 
produced when pre-treatment with LL-37 (Fig. 1A). In contrast, the IL-1β and IL-6 mRNA 
were decreased in LL-37 pre-treated BMDMs (Fig. 1B, C). Similar with previous reports, 
this results demonstrate that the complex of LL-37 and dsRNA helps to produce IFN-β. 
 
  




Figure 1. Pre-treatment with LL-37 increases IFN-β production by dsRNA in 
macrophages. BMDMs were pre-treated with LL-37 (20 µg/ml) for 1 hr, then followed 
by poly(I:C) (20 µg/ml) treatment for 6 hrs. The cells were used for the quantification of 
IFN-β (A), IL-6 (B) and IL-1β (C) mRNA levels by quantitative real-time PCR. The 
changes in the levels of each mRNA were normalized to the Rn18s and then the fold-
changes were calculated in comparison to corresponding untreated cells (n = 2). Statistical 
significance was determined by one-way ANOVA with a bonferroni post-test (*P<0.05).
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2. LL-37 regulates LPS-triggered pro-inflammatory cytokine production in 
macrophages  
In order to examine the association of the other TLR ligand with LL-37, BMDMs 
were treated with LPS, TLR4 agonists.37,38 The activation of TLR4 by LPS produces the 
pro-inflammatory cytokines such as IL-6, TNFα and pro-IL-1β. Recent studies have 
proposed pro-inflammatory cytokines are decreased in LL-37 pre-treated dendritic 
cells.28,29 To confirm the previous studies, the amount of secreted cytokines was confirmed 
by ELISA. BMDMs were treated with LL-37, followed by LPS treatment for 6 hrs. 
Contrary to the finding that LL-37 induces more IFN-β production, it is seen that LL-37 
inhibits IL-6 (Fig. 2A). However, Release of IL-1β is increased by LL-37 (Fig. 2B). These 
results predict that LL-37 is associated with inflammasome.  
 
  




Figure 2. LL-37 regulates the production of pro-inflammatory cytokine 
produced by LPS. BMDMs were treated with LL-37 (20 µg/ml) and then LPS (0.25 
µg/ml) treatment for 6 hrs. Cell culture supernatants were measured for the quantification 
of IL-6 (A) and IL-1β (B) by ELISA (n = 2). Statistical significance was determined by 
one-way ANOVA with a bonferroni post-test (*P<0.05).
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3. LL-37 induces the activation of NLRP3 inflammasome in LPS-primed 
macrophages 
Since previous data showed an increase in IL-1β by LL-37 (Fig. 2B), I tested 
the association with inflammasome that mainly releases IL-1β. The cells were 
stimulated with LPS, LL-37 and ATP in various ways, inflammasome is activated 
when LL-37 is treated after LPS priming (Fig. 3). In the culture supernatants of LPS 
and LL-37 treated BMDMs, the secretion of IL-1β was confirmed by western blot.  
The previous data confirmed the activation of inflammasome by LL-37 (Fig. 3). 
The following experiment was conducted to determine which inflammasome was 
dependent. BMDMs obtained from NLRP3 knock-out mice were used in the 
previous method (Fig. 4A). NLRP3 deficient BMDMs did not show inflammasome 
activity by LL-37. I also confirmed that ASC deficient BMDMs did not secrete the 
cleavage caspase-1 (p20) and IL-1β in culture supernatant (Fig. 4B). These data was 
shown that LL-37 induces NLRP3 dependent inflammasome activation in LPS-
primed BMDMs. 





Figure 3. LL-37 mediates the secretion of IL-1β and the cleavage of 
caspase-1 (p20) in LPS-primed macrophages. Immunoblots of BMDMs with 
LL-37 (15 µg/ml) treatment under various conditions. BMDMs were treated with 
LPS (0.25 µg/ml) for 3 hrs and then LL-37 for 3.5 hrs (line 2). After pre-treatment 
of LL-37 for 3.5 hrs in BMDMs, ATP (2.5 mM) was treated for 35 mins (line 3). 
BMDMs were treated with LL-37 for 3.5 hrs (line 4). LPS-primed BMDMs were 
treated with ATP for 35 mins. Cell culture supernatants (sup) or cellular lysates (Lys) 
were immunoblotted with the indicated antibodies. Unt: untreated, Pro-casp1: pro-
caspase-1, p20: active caspase-1. 
  




Figure 4. LL-37 treatment promotes NLRP3-dependent caspase-1 
activation in the presence of LPS priming. BMDMs were treated with LPS 
(0.25 µg/ml) for 3 hrs, followed by LL-37 (15 µg/ml) for 3.5 hrs. (A) Cell culture 
supernatants (sup) or cellular lysates (Lys) from wild type BMDMs and NLRP3 
knock-out BMDMs were immunoblotted with the indicated antibodies cultures. (B) 
Immunoblots from wild type BMDMs and ASC knock-out BMDMs cultures. The 
cells were treated in the same way as (A). Unt: untreated, Pro-casp1: pro-caspase-1, 
p20: active caspase-1. 
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4. LL-37 treatment triggers potassium efflux and calcium influx for 
NLRP3 inflammasome activation 
Signal 2–induced efflux of intracellular potassium and influx of extracellular 
calcium is generally considered a pivotal common phenomenon for the activation of 
NLRP3 inflammasome.39,40 To examine whether LL-37 treatment induced ions flux, 
the experiment was conducted using inhibitors such as KCl, glibenclamide and 
BAPTA-AM. KCl and glibenclamide both block potassium efflux and inhibit 
NLRP3 inflammasome activation. BAPTA-AM is a calcium chelator that lowers 
intracellular calcium levels. When three inhibitors were used in each experiment, all 
NLRP3 inflammasome acivation induced by LL-37 was inhibited in LPS-primed 
BMDMs (Fig. 5A-C). To determine whether the treatment of LL-37 is associated 
with ions transport, ion concentrations in cells were measured. LL-37 treatment 
caused a decrease in intracellular potassium and increase in intracellular calcium 
levels (Fig. 6). When LL-37 was treated, immunofluorescence (IF) was used to 
determine where it is located in the cell. The filamentous actin (F-actin) was stained 
with phalloidin and the location of LL-37 was confirmed. LL-37 began to adhere to 
the plasma membrane of the cells within 10 mins and confirmed entering into the 
cells within 2 hrs (Fig. 7). These results indicate that LL-37 treatment is mediated 
by ions movement for the activation of NLRP3 inflammasome. 
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Figure 5. Inhibition of ions flux prevents inflammasome activation by 
LL-37. BMDMs were treated with LPS (0.25 µg/ml) for 3 hrs. Then the cells were 
treated with KCl (40 mM, 1 hr) (A), Glibenclamide (30 µM, 1 hr) (B) or BAPTA-
AM (20 µM, 1 hr) (C), followed by treatment with LL-37 (15 µg/ml) for 3.5 hrs. 
Cell culture supernatants (sup) or cellular lysates (Lys) were immunoblotted with 









Figure 6. LL-37 induces the intracellular potassium efflux and 
extracellular calcium influx in LPS-primed macrophages. BMDMs were 
stimulated with LPS (0.25 µg/ml) for 3 hrs, followed by LL-37 (15 µg/ml) 
treatment for 1 hr. Intracellular potassium (A) and calcium (B) levels were 
measured by ICP-OES (n = 2). Statistical significance was determined by one-way 
ANOVA with a bonferroni post-test (n.s.. not significant; *P<0.05). 




Figure 7. LL-37 enters into the intracellular cytosol in LPS-primed 
macrophages. BMDMs were stimulated with LPS (0.25 µg/ml) for 3 hrs, 
followed by LL-37 (15 µg/ml) treatment for 10, 30 mins, 2hrs after staining with 
phalloidin (red) and anti-LL-37 (green). DAPI represents the nuclear signal (blue). 
Representative immunofluorescence images of BMDMs were observed by 
confocal microscopy.  
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5. LL-37 promotes the activation of NLRP3 inflammasome via inducing 
lysosomal rupture 
In the previous data (Fig. 7), I confirmed that LL-37 enters into the cells, so I 
examine the role of LL-37 in the cells in terms of inflammasome activation. 
Crystallin, such as MSU and Alum, is also known to activate inflammasome.41 
These types of stimuli are engulfed by phagocytosis and induce lysosome rupture in 
cells, resulting in cytosolic release of lysosomal contents.42 One of these contents, 
cathepsin B, activates NLRP3 inflammasome signaling. To examine whether LL-37 
is associated with lysosomal rupture, the cathepsin B inhibitor, CA-074, is used. 
CA-074 significantly reduced activation of inflammasome in LPS-primed BMDMs 
(Fig. 8). I used acridine orange to check if LL-37 releases cathepsin B through 
lysosomal rupture. Acridine orange detects pH changes in cells. Lysosomal rupture 
changes intracellular pH level. Flow cytometry data showed an increase in acridine 
orange staining after LL-37 treatment in LPS-primed BMDMs (Fig. 9). Next, I 
confirmed that LL-37 was co-located with the lysosome in the cells. The cells were 
stained with lysosomal-associated membrane protein 1 (LAMP1) antibody and 
confocal microscopy confirmed that LL-37 co-localized with lysosome (Fig. 10). 
Summarized, LL-37 enters the cells and encounters lysosomes, inducing lysosomal 
rupture, resulting in the release of cathepsin B, one of the lysosomal contents. As a 










Figure 8. LL-37 treatment activates inflammasome via cathepsin B in 
macrophages. BMDMs were stimulated with LPS (0.25 µg/ml) for 3 hrs. After 
then the cells were treated with CA-074 (40 µM) for 1 hr, followed by LL-37 (15 
µg/ml) treatment for 3.5 hrs. Cell culture supernatants (sup) or cellular lysates (Lys) 
were immunoblotted with the indicated antibodies. Unt: untreated, Pro-casp1: pro-
caspase-1, p20: active caspase-1.  




Figure 9. LL-37 induces lysosomal rupture in LPS-primed macrophages. 
The cells were treated with LPS (0.25 µg/ml) for 3 hrs, followed by LL-37 (15 
µg/ml, 3.5 hrs) or MSU (150 µg/ml, 3.5 hrs) treatment in absence or presence of 
bafilomycin (100 nM, 1 hr). Flow cytometric analysis to measure pH changes 
by LL-37 treatment in BMDMs.   




Figure 10. LL-37 co-localizes with the lysosome. BMDMs were treated 
with LPS (0.25 µg/ml, 3 hrs), followed by LL-37 (15 µg/ml, 4 hrs) after staining 
with anti-LAMP1 (green) and anti-LL-37 (red). DAPI represents the nuclear signal 
(blue). Representative immunofluorescence images of BMDMs were 
observed by confocal microscopy.  
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6. NLRP3 deficiency alleviates skin redness and inflamed blood vessels 
in rosacea mice model 
LL-37 is a peptide known to be mainly produced by epithelial cells and has 
been reported to be associated with the pathogenesis of skin diseases.43,44 Since the 
previous data confirmed that LL-37 is related to inflammasome activation (Fig. 4), a 
type of innate immune response, it is predicted that the inflammasome is related to 
skin disease. Among the many skin disorders, rosacea is not well-known for the 
cause of the disease and the treatment is not clear. In order to check the relationship 
between rosacea and inflammasome, I examined the rosacea mice model. To induce 
rosacea symptoms, I administered intradermal injection of LL-37 to wild type 
(Nlrp3+/+) and NLRP3 knock-out (Nlrp3-/-) mice and then examined the severity of 
disease via observation and skin thickness (Fig. 11A, B). As expected, 
administration of LL-37 induced skin redness and thickness like rosacea in wild 
type mice. In contrast, NLRP3 knock-out mice showed relatively fewer redness and 
thickness compared to wild type mice. Next, I observed changes in the amount of 
protein and RNA in skin tissues. Protein obtained from skin tissues was compared 
wild type and NLRP3 knock-out using western blot (Fig. 12A) and ELISA (Fig. 
12B) and checked the messenger RNA (mRNA) expression levels of inflammatory 
cytokine, IL-1β (Fig. 12C). Notably, LL-37 induced skin lesion was significantly 
protected by the NLRP3 knock-out mice. Furthermore, a significant reduction of IL-
1β mRNA was observed in the LL-37 treated NLRP3 knock-out mice, but not in 
wild type mice. Then, I checked the histopathological changes using hematoxylin-
eosin (H&E) staining (Fig. 12D). H&E Staining showed that the skin lesion of 
NLRP3 knock-out mice is much thinner than wild type mice. 
 
 




Figure 11. NLRP3 deficiency attenuates skin redness and inflammation 
in LL-37 injected mice. Wild type and NLRP3 knock-out mice were 
intradermally administered with PBS and LL-37 (50 or 300 µM, 40 µl) for 2 days 
and then observed skin surface images (A) and measured the skin thickness (B) (n = 
5). (C) Skin tissue was isolated for hematoxylin-eosin (H&E) staining. Statistical 
significance was determined by one-way ANOVA with a bonferroni post-test 
(***P<0.001). 




Figure 12. NLRP3 deficiency prevents the production of IL-1β and the 
abnormality of vascular in rosacea mice model. Mice were intradermally  
administered with PBS and LL-37 (50 or 300 µM, 40 µl) for 2 days and then skin 
tissue was isolated for western blot (A), ELISA (B), qPCR (C). (A) Immunoblot 
from skin tissue in wild type or NLRP3 knock-out mice. (B) ELISA of IL-1β 
protein levels in skin tissue treated with LL-37 (300 µM, 40 µl) (n = 4). (C, D) 
Quantification of IL-1β and VEGF mRNA levels in mice skin tissue treated with 
LL-37 (300 µM, 40 µl) as determined by qPCR (n = 3). Statistical significance was 
determined by one-way ANOVA with a bonferroni post-test (*P<0.05).  
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Ⅳ. DISCUSSION  
Recent studies suggested that LL-37 affects both pro-inflammatory response 
and anti-inflammatory response. Among them, LL-37 has been reported to be 
associated with the release of IL-1β, a major cytokine processed by inflammasome 
activation. However, the mechanisms underlying the contribution of LL-37 to 
inflammasome pathways remains unclear. In this study, I tried to demonstrate the 
mechanism of NLRP3 inflammasome activation by LL-37 and confirm that the 
activation of NLRP3 inflammasome affect the disease pathogenesis of rosacea.  
It has been verified that LL-37 increases the production of IFN-β as previously 
reported. The anti-inflammatory effect of LL-37 was also confirmed by LL-37/LPS 
complex, which reduced the cytokine produced by binding LPS to TLR4. In this 
study, it was confirmed that IL-1β was produced in BMDMs upon LPS and LL-37 
treatment. The activation of inflammasome requires priming by extracellular stimuli 
such as LPS or Pam3CSK4, which results in the transcriptional induction of pro-IL-
1β and NLRP3. After the priming, inflammasome is activated given the variety of 
DAMP stimuli, such as ATP or MSU. The following step was confirmed to 
determine whether the secretion of IL-1β is caused by inflammasome activation. 
The main potential is that LL-37 is associated with the inflammasome known to be 
primarily IL-1β production. Although LL-37 has been reported to produce IL-1β by 
activating the NLRP3 inflammasome, the molecular mechanism remains unclear 
and controversial.  
At first, the NLRP3 knock-out BMDMs were used to determine whether LL-
37 is associated with the NLRP3 inflammasome. NLRP3 deficient BMDMs 
significantly reduced IL-1β production by LL-37 compared to wild type BMDMs. 
In additions, the same result was observed in ASC deficient BMDMs. Then, to 
check the molecular mechanism for LL-37-mediated IL-1β production, I identified 
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ions movement, known as a common trigger for NLRP3 inflammasome activation. 
Several inhibitors such as KCl, glibenclamide or BAPTA-AM were used to confirm 
the possibility and LL-37-mediated Inflammasome activation was inhibited by these 
inhibitors. This result suggests that the activation of inflammasome by LL-37 was 
associated with ion transport. Furthermore, confocal microscopy data confirmed 
that LL-37 was attached to the plasma membrane. These results indicate that LL-37 
is involved in ions movement of cells. Based on the confocal microscopy data, I 
found LL-37 enters into the cells. A recent study reported that LL-37 was 
internalized into cell through P2X7 receptor-mediated endocytosis. However, 
because details of the internalization process underlying how LL-37 moves inside 
the cells are not found in this study, further studies are required to determine 
whether endocytosis-mediated internalization of LL-37 triggers NLPR3 dependent 
inflammasome activation.  
It has been reported that several skin diseases are associated with the 
overexpression of LL-37. Previous data have shown that LL-37 induces the 
production of IL-1β by activating inflammasome, suggesting the association 
between inflammasome and skin disease. In this study, I used rosacea mice model, 
which is a skin disease with excessive increase of LL-37. Recent studies showed 
that rosacea was induced by intradermal injection of LL-37 on the mice back and 
confirmed by H&E staining or vascular abnormalities factor such as VEGF or CD31. 
To determine whether NLRP3 inflammasome affect rosacea disease induction, 
rosacea was induced by intradermal injection of LL-37 in both wild type and 
NLRP3 knock-out mice. The severity of the rosacea phenotype was assessed, based 
on the skin surface images and thickness change. It was confirmed that rosacea was 
induced normally in wild type mice, but not in NLRP3 knock-out mice, indicating 
that NLRP3 has a critical role in the pathogenesis of rosacea. Currently, There is no 
the proper treatment available for rosacea, except for laser treatment, powerful oral 
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acne drugs such as isotretinoin or oral antibiotic such as doxycycline. This study 
indicates that the activation of NLRP3 inflammasome is a novel factor for rosacea 
pathogenesis. Therefore, it suggests that regulation of NLRP3 inflammasome is a 
potent therapeutic target for rosacea disease. Whether MCC950 or IL-1 receptor 
antagonist (IL-1Ra), anakinra, which can be used as a therapeutic agent for 
inflammasome, is effective for rosacea, this study is not found. Therefore, further 
investigation are required to determine possibility of MCC950 or anakinra as 
treatment for rosacea.  
Collectively, this study reveals the mechanism for how LL-37 activates NLRP3 
inflammasome and also indicates that NLRP3 inflammasome plays a crucial role in 
rosacea disease. Therefore, I suggest that NLRP3 inflammasome signaling might be 











Here, I demonstrated that LL-37 activates NLRP3 dependent inflammasome. 
Moreover, NLRP3 inflammasome activation by LL-37 is mediated by potassium 
efflux, calcium influx and lysosomal rupture. I also showed that NLRP3 deficiency 
in mice had protective effects on LL-37 injected rosacea mouse model. I observed 
LL-37 injected NLRP3 deficiency mice attenuated skin redness and abnormality of 
vascular compared to LL-37 injected wild type mice. Collectively, all these data 
produce evidence that the activation of NLRP3 inflammasome has a crucial role in 
rosacea skin disease. Because the alleviation of rosacea disease was observed in 
NLRP3 knock-out mice, further studies is needed to determine whether MCC950 or 
IL-1 receptor antagonist (IL-1Ra), anakinra associated with NLRP3 inflammasome 
inhibitor treatment can attenuate rosacea. If further studies are conducted to confirm 
that MCC950 or anakinra treatment can be attenuated in rosacea, then it could be 
the therapeutic target.   
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ABSTRACT (in Korean) 
 








항균펩티드는 천연 항생제 역할을 할 수 있는 물질이다. LL-
37 은 항균펩티드 중에서 카델리시딘의 종류 중 하나로써, 주로 
표피세포에서 많이 생산되고, 박테리아 감염이 일어났을 때, 
빠르게 일어나는 방어 기작으로 선천면역반응에 있어 중요한 
역할을 한다. LL-37 은 IFN-β 의 생산은 증가시키고, IL-6 의 
생산은 감소시킨다는 보고가 있다. 그러나 현재까지 면역 
반응에서의 LL-37 의 역할은 명확하게 밝혀진 것이 없다. 최근 
연구에서 LL-37 이 주사나 건선과 같은 피부 질환에서 과도하게  
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증가되어 있다라는 것이 밝혀졌다. 그 중에서도 주사 피부질환의 
병인기전은 아직까지 밝혀진 것이 없다. 본 연구에서는 선천 
면역반응에서 LL-37 의 역할을 확인해보고자 하였다. 마우스 골수 
대식세포에서 LL-37 에 의해 NLRP3 인플라마좀의 활성이 
유도된다는 것을 확인하였고, 또한 NLRP3 인플라마좀의 활성이 
유도되는 과정을 밝혔다. LL-37 에 의해 나타나는 NLRP3 
인플라마좀 활성 측면에서 칼륨의 유출과 칼슘의 유입의 억제가 
인플라마좀 활성을 저해하는 것을 확인하였고, LL-37 이 세포 
내부로 들어가 리소좀을 파괴시켜 cathepsin B 가 유출되어 NLRP3 
인플라마좀이 활성화 된다는 것을 확인하였다. 그 이후에 LL-37 
을 주입하여 주사 질병을 유도하였을 때, NLRP3 인플라마좀의 
활성이 잠재적인 역할을 할 것이라고 확인하였다. 흥미롭게 NLRP3 
결핍 마우스에서 병변 완화와 IL-1β 의 유출의 감소를 
확인하였다. 위의 결과들을 토대로 본 연구에서는 LL-37 에 의한 
NLRP3 인플라마좀의 활성이 주사 질병에 중요한 역할을 하고 
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